Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, D.-H. | - |
dc.contributor.author | Choi, S. | - |
dc.contributor.author | Park, Y. | - |
dc.contributor.author | Jin, H.-S. | - |
dc.date.accessioned | 2024-01-19T13:33:31Z | - |
dc.date.available | 2024-01-19T13:33:31Z | - |
dc.date.created | 2022-01-10 | - |
dc.date.issued | 2021-10 | - |
dc.identifier.issn | 1424-8247 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/116307 | - |
dc.description.abstract | The mucin (MUC) family is a group of highly glycosylated macromolecules that are abundantly expressed in mammalian epithelial cells. MUC proteins contribute to the formation of the mucus barrier and thus have protective functions against infection. Interestingly, some MUC proteins are aberrantly expressed in cancer cells and are involved in cancer development and progression, including cell growth, proliferation, the inhibition of apoptosis, chemoresistance, metabolic reprogramming, and immune evasion. With their unique biological and structural features, MUC proteins have been considered promising therapeutic targets and also biomarkers for human cancer. In this review, we discuss the biological roles of the transmembrane mucins MUC1 and MUC16 in the context of hallmarks of cancer and current efforts to develop MUC1-and MUC16-targeted therapies. ? 2021 by the authors. Licensee MDPI, Basel, Switzerland. | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.title | Mucin1 and mucin16: Therapeutic targets for cancer therapy | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/ph14101053 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | Pharmaceuticals, v.14, no.10 | - |
dc.citation.title | Pharmaceuticals | - |
dc.citation.volume | 14 | - |
dc.citation.number | 10 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000716390800001 | - |
dc.identifier.scopusid | 2-s2.0-85117912459 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Review | - |
dc.subject.keywordPlus | EPITHELIAL OVARIAN-CANCER | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTOR | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | CARCINOMA-ASSOCIATED ANTIGEN | - |
dc.subject.keywordPlus | MUC1 ONCOPROTEIN | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | TUMOR-MARKER | - |
dc.subject.keywordPlus | CA 125 | - |
dc.subject.keywordPlus | IMMUNOLOGICAL RESPONSE | - |
dc.subject.keywordPlus | MAINTENANCE THERAPY | - |
dc.subject.keywordAuthor | ADC (antibody-drug conjugate) | - |
dc.subject.keywordAuthor | Cancer vaccine | - |
dc.subject.keywordAuthor | CAR (chimeric antigen recep-tor) | - |
dc.subject.keywordAuthor | Immunotherapy | - |
dc.subject.keywordAuthor | MUC1 | - |
dc.subject.keywordAuthor | MUC16 | - |
dc.subject.keywordAuthor | Mucin | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.